Journal Article Multicenter Study Epublish
PubMed: 40136987 DOI: 10.3390/bios15030190
The Usefulness of the Glucose Management Indicator in Evaluating the Quality of Glycemic Control in Patients with Type 1 Diabetes Using Continuous Glucose Monitoring Sensors: A Cross-Sectional, Multicenter Study.
Biosensors (Basel) 15(3)
Authors: Sandra Lazar, Ovidiu Potre, Ioana Ionita, Delia-Viola Reurean-Pintilei, Romulus Timar, Andreea Herascu, Vlad Florian Avram, Bogdan Timar
Affiliations
- First Department of Internal Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Department of Hematology, Emergency Municipal Hospital, 300254 Timisoara, Romania.
- Centre for Molecular Research in Nephrology and Vascular Disease, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Multidisciplinary Research Center for Malignant Hematological Diseases (CCMHM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Department of Medical-Surgical and Complementary Sciences, Faculty of Medicine and Biological Sciences, "Stefan cel Mare" University, 720229 Suceava, Romania.
- Department of Diabetes, Nutrition and Metabolic Diseases, Consultmed Medical Centre, 700544 Iasi, Romania.
- Second Department of Internal Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Department of Diabetes, "Pius Brinzeu" Emergency Hospital, 300723 Timisoara, Romania.
Abstract
The Glucose Management Indicator (GMI) is a biomarker of glycemic control which estimates hemoglobin A1c (HbA1c) based on the average glycemia recorded by continuous glucose monitoring sensors (CGMS). The GMI provides an immediate overview of the patient's glycemic control, but it might be biased by the patient's sensor wear adherence or by the sensor's reading errors. This study aims to evaluate the GMI's performance in the assessment of glycemic control and to identify the factors leading to erroneous estimates. In this study, 147 patients with type 1 diabetes, users of CGMS, were enrolled. Their GMI was extracted from the sensor's report and HbA1c measured at certified laboratories. The median GMI value overestimated the HbA1c by 0.1 percentage points (p = 0.007). The measurements had good reliability, demonstrated by a Cronbach's alpha index of 0.74, an inter-item correlation coefficient of 0.683 and an inter-item covariance between HbA1c and GMI of 0.813. The HbA1c and the difference between GMI and HbA1c were reversely associated (Spearman's r = -0.707; p < 0.001). The GMI is a reliable tool in evaluating glycemic control in patients with diabetes. It tends to underestimate the HbA1c in patients with high HbA1c values, while it tends to overestimate the HbA1c in patients with low HbA1c.
MeSH
Diabetes Mellitus, Biomarkers, Diabetes Mellitus, Type 1, Glycemic Control, Continuous Glucose Monitoring